HCPCS code J0713: Injection, ceftazidime, per 500 mg

Key takeaways

HCPCS code J0713 covers an injection of ceftazidime, a third-generation cephalosporin antibiotic, billed per 500 mg administered.

Medicare Part B pays J0713 at ASP+6% in the office setting, while hospital outpatient claims may be packaged under OPPS.

Every J0713 claim must carry the NDC in loop 2410 of the 837P, and a missing NDC is the top rejection trigger.

J0713 is absent from the CMS list of codes subject to the JW and JZ policy, so no discard modifier is expected.

Practice management software like Pabau captures the dose, unit count, and NDC at the point of care.

HCPCS code J0713 is the Level II code for an injection of ceftazidime, billed per 500 mg of drug administered. It sits within the J0001-J8999 drug administration range maintained by the Centers for Medicare and Medicaid Services (CMS). Ceftazidime goes in intravenously or intramuscularly, and Medicare Part B pays for it as a physician-administered drug.

The code has no expiration date and remains active for the current fiscal year. Coverage is subject to Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs). An LCD may add medical necessity criteria, and those criteria vary by jurisdiction.

Ceftazidime: Clinical context and FDA-approved indications

Ceftazidime is a broad-spectrum beta-lactam antibiotic that works mainly against gram-negative organisms. It blocks bacterial cell wall synthesis and covers Pseudomonas aeruginosa, a pathogen many other antibiotics miss. Practices that handle prescription management for infusion patients meet J0713 in serious hospital-acquired and community-acquired infections.

The FDA has approved ceftazidime for the following indications, all of which support medical necessity for a J0713 claim:

• Lower respiratory tract infections, including pneumonia
• Urinary tract infections (UTIs), complicated and uncomplicated
• Bacterial meningitis
• Septicemia and bacteremia
• Febrile neutropenia (inpatient and outpatient infusion)
• Skin and skin-structure infections
• Intra-abdominal infections
• Bone and joint infections

Outpatient infusion suites treat the sickest of these cases, while primary care practices see more complicated UTIs and skin infections. Brand-name products include Fortaz (Covis Pharma) and Tazicef (Pfizer). Generic formulations are more commonly dispensed in practice settings today, so verify each manufacturer’s current NDC against the FDA NDC Directory.

J0713 billing units and dosage calculation

Units for HCPCS code J0713 are calculated per 500 mg administered, not per vial or per infusion session. If a patient receives a 2 g dose, the correct unit count is 4 (2,000 mg divided by 500 mg). Billing the wrong unit count is the single most common J0713 error, and it triggers both underpayments and overpayment audits.

Bill the dose given, not the dose in the vial. Suppose 1.5 g is ordered but the infusion stops after 1 g. Bill 2 units, then document why the dose changed.

JW and JZ modifiers on a J0713 claim

J0713 does not take a JW or JZ modifier. CMS applies those two modifiers to drugs supplied in single-dose containers, and J0713 is not on its published list of affected codes.

The JW modifier reports a discarded amount of a drug, and JZ confirms that nothing was discarded. Any code with a multiple-dose container product is left off the CMS list, which is where ceftazidime sits. Its neighbors J0712 and J0714 are both on the list, so a ceftazidime and avibactam line does need the modifier.

CMS refreshes the discard modifier code list roughly twice a year. Check it before you change a billing rule, and follow your MAC if a local article says otherwise.

Medicare Part B reimbursement for HCPCS code J0713

Medicare Part B covers physician-administered drugs under the buy-and-bill model. In an office or non-facility setting (Place of Service 11), J0713 pays at ASP+6%. That is the Average Sales Price for the quarter, plus a 6% add-on toward acquisition costs. Practices handling IV therapy billing meet this model across most infusion drug J-codes.

CMS updates ASP pricing quarterly. Rates effective for a given quarter are published in the CMS ASP Drug Pricing Files, available on the CMS Physician Fee Schedule lookup tool. Do not use prior-quarter figures. A claim submitted in Q3 with Q2 ASP rates can pay at the wrong amount.

Place of service impact on J0713 rates

The place of service code on the claim decides how J0713 is paid. Office claims (POS 11) pay ASP+6% under the Medicare Physician Fee Schedule. Hospital outpatient claims (POS 22) fall under the Outpatient Prospective Payment System (OPPS). There, J0713 may be packaged into the Ambulatory Payment Classification (APC) payment instead of paying as a separate line.

Provider-based practices are owned by a hospital system. If that describes yours, confirm with your MAC whether OPPS packaging applies before you bill J0713 as a separate line.

Buy-and-bill model for ceftazidime billing

Buy-and-bill is the standard payment pathway for physician-administered drugs under the Medicare Part B benefit. The practice buys the drug, administers it, then bills the payer for the drug and the administration service. Clean drug inventory management is what keeps that cycle straight.

Here is the step-by-step process for J0713 under the buy-and-bill model:

1. Purchase ceftazidime from a licensed wholesaler or specialty pharmacy. Track the NDC, lot number, and acquisition cost per unit.
2. Administer the drug per the physician’s order. Document the exact dose administered, route, and time in the patient record.
3. Calculate billing units using the 500 mg increment formula (dose in mg divided by 500).
4. Select the correct administration code alongside J0713. CMS requires a separate drug administration CPT code. Use 96374 for an IV push, 96365 for an IV infusion of up to one hour, and 96360 for hydration.
5. Report the NDC in loop 2410 of the 837P electronic claim or in the appropriate field of the UB-04. This is mandatory for all Medicare Part B drug claims.
6. Submit the claim with the correct POS code, diagnosis code(s), and the J0713 line item at the correct unit count.

Most injectable J-codes follow this same structure, and only the unit denominator changes. J0744 bills ciprofloxacin in 200 mg units, so the same milligram total produces a different unit count.

NDC crosswalk: Drug products mapped to HCPCS code J0713

Every J0713 claim sent to Medicare needs the National Drug Code (NDC) of the ceftazidime product administered. The NDC ties the manufacturer, product, and package size to the billing code. Missing or wrong NDCs are a primary cause of claim rejection. Verify your mappings against the crosswalk your MAC publishes.

Report the NDC in 11-digit format (5-4-2: labeler-product-package). The NDC on the claim must match the NDC on the vial you administered, not a substitute or preferred contract NDC. An NDC from a different manufacturer than the vial you used is a compliance risk.

ICD-10 diagnosis codes commonly billed with HCPCS code J0713

The right ICD-10-CM diagnosis code is what establishes medical necessity for a J0713 claim. The diagnosis must reflect the condition treated with ceftazidime, in line with its FDA-approved indications. Pairing J0713 with a diagnosis outside those indications is a common audit trigger.

Use the most specific ICD-10 code available. Sepsis, unspecified (A41.9) works at initial presentation, but update it once cultures identify the organism. Pneumonia coding works the same way, and J13 replaces a generic code once the organism is confirmed. MACs review diagnosis specificity during audits, and vague codes invite scrutiny.

Documentation requirements for J0713 claims

CMS expects specific documentation elements behind a J0713 claim. Incomplete records are the second most common cause of denial and the main finding in post-payment audits. Capture these elements at the point of care rather than rebuilding them later. The same list applies to other injectable antibiotic codes, including J0561.

• Physician order: a signed order specifying ceftazidime, dose, frequency, and route of administration
• Diagnosis: the ICD-10-CM code(s) that establish medical necessity, with clinical notes supporting the diagnosis
• Drug name and strength: documented in the administration record (“ceftazidime 1 g IV” not “antibiotic IV”)
• Dose administered: the exact milligram amount given, not the ordered dose if different from what was given
• Route of administration: IV push, IV infusion, or IM, matching the administration code billed
• Date and time of service: required for all infusion drugs; time matters for multiple-infusion-session billing on the same day
• Place of service: documented in the record and consistent with the POS code on the claim
• NDC number: the 11-digit NDC of the ceftazidime vial actually used, recorded in the administration record

MACs may request the drug order, the nursing administration record, and progress notes together during a probe audit. With all eight elements in place, your records answer the request on their own.

Common billing errors and how to avoid them with HCPCS code J0713

Six errors account for most J0713 denials and recoupments, and each one has a fix. Automating inventory tracking removes several at the source. It captures the NDC and the quantity as the drug is given, instead of leaving them to manual entry at claim time.

Related HCPCS J-codes for antibiotic injections

Coders auditing ceftazidime claims often need the adjacent cephalosporin J-codes to hand. Knowing them cuts crossover errors when the treating physician switches antibiotic regimens mid-course. Each code below carries its own unit denominator, so check the unit before you convert a dose.

J0713 and J0692 get mixed up in Pseudomonas coverage decisions. Cefepime is a fourth-generation cephalosporin with broader antipseudomonal activity. Confirm which drug was given before you assign the code. Both bill per 500 mg, so the unit count hides the swap and only the drug name gives it away.

How Pabau keeps J0713 claims clean

In most practices, the details a J0713 claim needs sit in three places. The nurse writes the dose on the administration record. The vial NDC sits on a purchase invoice, and the biller converts milligrams to units days later. Every hop is a chance for the unit count or the NDC to drift.

Practice management software like Pabau closes that distance. Ceftazidime is held as a stock item, so giving a dose deducts the vial and writes the product and amount into the patient record. The biller then works from what the nurse recorded, not from a phone call two days later.

From there, Pabau’s claims management tools carry the drug line onto the claim with its unit count and place of service. Denials come back grouped, so a repeat J0713 reason code shows up in a report rather than in a spreadsheet someone maintains by hand. Your team spends the week treating patients instead of reconciling vials against claims.

Bill drug codes from the record, not by hand

Pabau keeps drug stock, dosing, and claims in one system. The unit count and product details on a J0713 line come from the record your team already completed.

Book a demo

Conclusion

J0713 is a quiet code that punishes small slips. The arithmetic is simple, but the unit count, the NDC, and the place of service all have to be right on the same line.

Where the work happens is the trade-off worth remembering. Fixing a J0713 line at claim time costs a biller time and a resubmission. Capturing the dose and the NDC at the chairside costs nothing extra. Routine is worth checking too, so look at the CMS discard modifier list before anyone adds JW or JZ out of habit.

Book a demo to see how Pabau turns an administration record into a clean drug claim.

Continue your research

Billing another injectable drug code? J0270 covers alprazolam injection, where the same unit and NDC rules meet a controlled substance.

Screening patients before you treat them? H0049 sets out how to bill alcohol and drug screening in an outpatient setting.

Billing supplies by the unit? B4104 shows how per-unit rules work for an enteral formula additive.

Wondering what OPPS packaging swallows? C1776 covers an implantable joint device, where packaging decides whether the line pays.

Frequently asked questions